Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors.

ABSTRACT: In international guidelines, influenza vaccination is recommended to cancer patients receiving antitumor treatment. Whether this recommendation should include patients treated with the recently introduced and now widely used checkpoint inhibitors (CPIs) is unclear. The immune hyperactivation after vaccination in a patient on CPI treatment may strengthen the antitumor immunity and improve patients´ prognosis. On the other hand, the hyperactivation might increase the risk for immune-related adverse events (IRAEs). Furthermore, there is a risk for decreased antitumor effect by the phenomenon of antigenic competition. Only results from few studies addressing survival have been reported and the results from studies on IRAEs are contradictory. We performed a multi-center retrospective cohort stu

SUBMITTER: Valachis A 

PROVIDER: S-EPMC7894446 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature